Professional Documents
Culture Documents
Beta-Blockers in Cirrhosis: Evidence-Based Indications and Limitations
Beta-Blockers in Cirrhosis: Evidence-Based Indications and Limitations
Portosystemic
Increased intrahepatic collaterals
resistance
Carvedilol β1-adrenergic
blockade
NSBB
Architectural Dynamic
↑ Cardiac ↓ Cardiac output
Varices output and heart rate
Fig. 1. Pathophysiology of portal hypertension in cirrhosis and mechanisms and sites of action of non-selective beta-blockers. NSBB, non-selective beta
blocker.
>1 RCT failed to 1 RCT in Various RCT meta- Various RCT Prevention of first 1 RCT:
show prevention of compensated analyses: meta-analyses: bleeding GOV1-2, - Decreases
large varices and patients with CSPH - Decreases bleeding - Decreases IGV1: rebleeding
more adverse - Improves survival rebleeding III;2 No RCT designed
events - Improves survival Indication for prevention of
Compensated and first bleeding:
high-risk varices: Patients without Prevention of
I;1 and with ascites rebleeding:
I;1 I;1 Decompensated and previous variceal cyanoacrylate
I;1
GRADE 1 GRADE 1 and high-risk varices: bleeding: superior (RCT) and
GRADE 1
Level 1b Level 1b I;1 no additional benefit
Level 1b
I;1 from NSBB
Both GRADE 1 GRADE 1 GRADE 2,
Level 1a Level 1a Level III
Fig. 2. Levels of evidence for non-selective beta-blockers in cirrhosis according to indication. CSPH, clinically significant portal hypertension;
GOV1-2, gastroesophageal varices type 1/2; IGV1, isolated gastric varices type 1; NSBB, non-selective beta blocker; RCT, randomised controlled trial.
reflecting a favourable impact on the natural history of the absolute risk reduction of first variceal haemorrhage within
disease; this is one of the advantages of NSBBs compared to 2 years of follow-up was −10% in patients with NSBBs vs. pla-
endoscopic therapy. The level of evidence for NSBB use in the cebo. A small decline in absolute mortality rate, of −4% was
main indications of cirrhosis is summarised in Fig. 2. found, approaching statistical significance. When the analysis
was stratified to patients with high-risk varices, the bleeding
rate in treated patients diminished significantly, by −16%.27
Indications In 2012, a meta-analysis of 19 trials suggested that EBL was
Prevention of first variceal bleeding (primary prophylaxis) slightly superior to NSBBs for primary prophylaxis of variceal
Patients with high-risk varices and compensated cirrhosis bleeding (risk ratio [RR] 0.67; 95% CI 0.46–0.98; p = 0.037).
Currently, NSBBs and endoscopic band ligation (EBL) are consid- However, on further analysis, no significant differences were
ered equally effective in preventing first bleeding in patients with found either in bleeding-related or overall mortality compared
high-risk varices,22–24 i.e. medium to large varices or small varices with NSBBs in high-quality trials. Complications or side effects
with red wale marks or in patients with decompensated cirrhosis associated with EBL are less frequent, but more severe and
(Child-Pugh B/C).22,25 NSBBs are favoured over endoscopic ther- potentially fatal.28,29
apy in patients with small, high-risk varices, given the size of the Regarding carvedilol, the first RCT comparing carvedilol to
varices.22 EBL30 reported that carvedilol had lower rates of the first variceal
In patients with compensated cirrhosis and high-risk varices, bleed (10% vs. 23%, p = 0.04), with no significant differences in
the primary goal of therapy is not limited to bleeding preven- overall mortality (35% vs. 37%, p = 0.71), and bleeding-related
tion (that is not the most common event), but must also focus mortality (3% vs. 1%, p = 0.26), but did not report data on other
on preventing decompensation of cirrhosis (ascites, variceal events. Thirty percent of patients in both arms dropped out and
bleeding or hepatic encephalopathy). However, the vast major- per-protocol analysis revealed no significant differences in out-
ity of studies were only designed to evaluate reductions in the comes; in addition, the study was underpowered. Another study
risk of haemorrhage and subsequent bleeding-related death. showed that, in propranolol non-responders, carvedilol could
Moreover, most studies included both compensated and effectively decrease HVPG; during a 2-year follow-up, bleeding
decompensated patients. As stated above, it is now preferred to rates for propranolol were 11% compared to 5% with carvedilol and
consider therapy according to the stage of the disease; treating 25% with EBL (p = 0.04).19 A further trial in Pakistan showed that
compensated patients to prevent decompensation and decom- both EBL and carvedilol monotherapy groups had comparable
pensated patients to prevent liver transplantation and death. variceal bleeding (8.5% vs. 6.9%), bleeding-related mortality (4.6%
Considering this, pharmacological therapy may be a better vs. 4.9%) and overall mortality rates (12.8% vs. 19.5%), respec-
approach than endoscopic treatment, given its ability to prevent tively.31 An additional study comparing EBL vs. propranolol and
decompensation. It is well known that ascites may be prevented carvedilol showed comparable rates of bleeding prevention.32
in haemodynamic responders to NSBBs,13 while this is not Again, these studies provide no data on prevention of other com-
possible with endoscopic treatments. plications of PH. Presently, there is still insufficient data showing
NSBBs are effective in preventing first bleeding event in pa- superiority of either EBL or carvedilol therapy in primary preven-
tients with cirrhosis, independent of disease severity.26 In 1999, tion of bleeding. The ongoing CALIBRE multicentre UK trial is
a meta-analysis of RCTs selected 8 studies including patients designed to compare carvedilol to EBL in prevention of bleeding.33
with medium-large varices. This meta-analysis compared NSBBs These results are awaited, particularly regarding impact on pre-
(propranolol/nadolol) to placebo or nonactive treatment and venting other liver-related complications.
demonstrated a clear reduction in absolute risk of bleeding and A network meta-analysis using data combining direct and
bleeding-related mortality, but not overall mortality.27 The indirect evidence from 32 RCTs including 3,362 patients with
cirrhosis with high-risk varices assessed the effect of different carvedilol use and decompensated cirrhosis, showed increased
treatment modalities on first episode of variceal bleeding survival in the carvedilol group vs. non-carvedilol groups
and mortality. Regarding bleeding prevention, on direct meta- (24% vs. 2%, p <0.0001). The long-term survival was significantly
analysis, EBL monotherapy reduced the risk of first variceal better in the carvedilol than the non-carvedilol group (log-rank
bleed compared to placebo (odds ratio [OR] 0.36; 95% CI p <0.001).44
0.14–0.92), to NSBB (OR 0.52; 95% CI 0.35–0.78), and to iso-
sorbide mononitrate (ISMN) (OR 0.25; 95% CI 0.07–0.93). EBL Prevention of the formation or growth of varices
monotherapy was associated with a higher risk of overall (preprimary prophylaxis)
mortality compared with NSBBs, although not significant (OR Patients with no varices or non-high-risk varices and compensated
1.35; 95% CI 0.98–1.86). Side effects were more common with cirrhosis
NSBBs, leading to 10–13% rates of treatment discontinuation, Presently, there is not enough evidence to support the use of
but almost all of the serious adverse events were related to NSBBs to prevent the development or growth of varices in pa-
EBL.34 Six RCTs within this meta-analysis compared combined tients with cirrhosis without varices or with small varices
EBL or ISMN and NSBBs to monotherapy and demonstrated without red wale signs. One French study evaluated the effect of
that combination therapy significantly reduced first variceal propranolol on preventing the development of large oesopha-
bleeding compared with placebo (OR 0.34; CI 0.14–0.86). geal varices over 2 years in patients with or without small
However, in the trials of combined therapy, adverse events were varices.45 More than twice the patients assigned to propranolol
reported in 59% of patients receiving a combination of EBL and developed varices compared to placebo, but one-third of the
NSBBs, in 51% of patients receiving carvedilol monotherapy and patients were lost to follow-up, in addition to those who sus-
ranged between 20–24% for those receiving other NSBBs or EBL pended therapy because of intolerance. Bleeding and mortality
or ISMN or combined NSBB+ISMN.34 The 2 existing trials on rates were similar. A multicentre, single, double-blind RCT of
combined endoscopic and NSBB therapy vs. monotherapy timolol vs. placebo showed that, after 55 months, 39% and 40%
showed no added benefit.7,35 In 2017, a multicentre RCT from of patients in the timolol and placebo groups, respectively,
Korea reported that propranolol + EBL was more effective for developed varices. Additionally, adverse events were more
primary prophylaxis in patients with high-risk varices. More- frequent in the timolol group. However, the study disclosed that
over, combination therapy was more effective in the prevention the development of large varices, variceal bleeding, ascites,
of variceal recurrence after EBL eradication. Adverse event rates encephalopathy, and death did not occur when HVPG remained
were not described.36 It is still unclear whether combination below 10 mmHg, and that varices developed much less
therapy is more effective and safer for primary prophylaxis. frequently when HVPG was decreased by over 10% of baseline.
Although current guidelines recommend either NSBBs or EBL as A therapeutic benefit of timolol in preprimary prophylaxis
equivalent therapies for primary prophylaxis, recent evidence could not be established.46 Among possible causes are sample
shows that NSBBs in patients with compensated cirrhosis and size distribution and inclusion of patients without CSPH (HVPG
clinically significant portal hypertension (CSPH) can prevent <10 mmHg). Around 50% of the patients did not have CSPH and,
first decompensation, namely ascites. Thus, since EBL is not thus, had not fully developed a hyperdynamic circulatory state.
likely to prevent ascites, NSBBs are emerging as the preferred At this stage, the effect of propranolol on portal pressure has
option.13 been shown to be almost negligible.47
More recently, Sarin et al. showed that in patients with
Patients with high-risk varices and decompensated cirrhosis cirrhosis and small oesophageal varices, NSBBs were unable to
The potential limitations of NSBBs in end-stage cirrhosis will prevent the growth of varices, variceal haemorrhage, or mor-
be discussed later in a dedicated section. There is firm data tality.48 In contrast, 2 studies showed evidence in favour of beta-
supporting NSBB use in the prevention of first variceal blockers to delay growth of small varices. One RCT comparing
bleeding event in both patients with and without ascites. An nadolol to placebo reported cumulative risks of variceal pro-
individual patient meta-analysis of 4 RCTs showed that NSBBs gression in 20% vs. 51%, for the nadolol and placebo groups,
effectively prevent the first episode of variceal bleeding and respectively. The cumulative probability of variceal bleeding
reduce bleeding-related mortality independently of cirrhosis was also lower in patients randomised to nadolol (p = 0.02).
stage.26 The 2-year bleeding rate was reduced by 9%. The risk Survival was not different and adverse effects resulting in
decrease was observed in patients with ascites (−14%) and withdrawal were more common in the nadolol group.49 Car-
without ascites (−15%). According to the log-rank test on vedilol was tested in another RCT against placebo to assess the
Kaplan-Meier cumulative estimates, the reduction in first delay in small varices progression; this study showed that 79%
bleeding episode was statistically significant (from 41% to 27%, of patients in carvedilol group vs. 61% of patients in placebo
p = 0.002).26,27 group were free from progression to large varices (p = 0.04).
Furthermore, a meta-analysis on prevention of first bleeding No differences were found regarding bleeding events, mor-
and rebleeding analysed both patients with cirrhosis with and tality or adverse side effects.50 A meta-analysis of 6 RCTs
without ascites, who responded to treatment with NSBB (based including patients with no or small varices found no signifi-
on reductions in HVPG), and demonstrated a reduced risk of cant benefit for NSBBs compared to placebo for the prevention
liver-related events, death, or liver transplantation.37 of large varices, first variceal bleeding and death.51 Overall, the
Following 2 observational studies, concerns regarding beta- evidence is conflicting regarding an impact of beta-blockers on
blocker use in the context of ascites11 or SBP38 were raised. slowing the progression of small varices to large varices in
Since then, various studies questioned the validity of the find- patients with cirrhosis. At this stage, treatment should be
ings and showed that in decompensated patients NSBB use centred on eliminating or controlling the cause of liver disease
improved survival39–43 or showed no difference.41 A retrospec- to attempt regression of architectural changes and reduction
tive study of 264 propensity score matched patients under of intrahepatic resistance. Furthermore, it is currently accepted
Prevention of first bleeding groups had a lower risk of PHG compared to those under
The 2 most widely used treatments in this context are NSBBs endoscopic therapy.32
and endoscopic variceal obliteration with tissue adhesive in- In patients with previous acute or chronic bleeding, the
jection. Solid data from RCTs is too scarce to demonstrate su- benefit of beta-blockade is more established. Current guidelines
periority of cyanoacrylate variceal obliteration over NSBBs. One recommend NSBBs as first line therapy in preventing recurrent
RCT reported a higher rate of first bleeding episodes in patients bleeding from PHG.22 An RCT in patients with cirrhosis and PHG
with cardiofundal varices (GOV2 and IGV1) in the group treated reported PHG-associated rebleeding rates of 65% in controls
with NSBBs compared to cyanoacrylate injection (38% vs. 10%, vs. 38% in patients under propranolol (doses 40–320 mg/d)
p = 0.003), with similar survival rates (83% vs. 74%, p = 0.113).62 (p <0.05). At 30 months, over 50% of patients on propranolol did
Guidelines advocate NSBBs for primary bleeding prophylaxis of not experience rebleeding compared to less than 10% of con-
GOV2 and IGV1 based on a potential lower risk of complications trols.6 An earlier, smaller study involving 38 patients with PHG
and the possibility of clinical decompensation prevention. GOV1 (14 with acute bleeding and 24 with nonbleeding PHG)
varices should be treated per guidelines for oesophageal varices described a decrease in the incidence of rebleeding and a
(either NSBBs or EBL).22,23 reduction in PHG with propranolol.71
Acute bleeding associated with PHG is rare. A multicentre
Management of acute bleeding and prevention of rebleeding study reported a 2.5% rate of acute PHG-related bleeding during
Medical treatment of acute bleeding from gastric varices is a mean follow-up period of 18 months.72 The evidence sup-
similar to oesophageal varices, except that the preferred porting NSBBs during bleeding events is very scarce.71 Current
endoscopic therapy for gastric varices is variceal obliteration guidelines advocate beta-blockers for secondary prophylaxis
with endoscopic cyanoacrylate injection.23 Assessment is after adequate bleeding control with faster-acting vasoactive
complicated by the fact that many studies have small samples drugs.22
and include patients with GOV1 varices and different aetiol-
ogies of PH, including some patients with extrahepatic portal
vein occlusion or idiopathic PH. A single RCT with 95 patients Beta-blocker contraindications, dosage and side
concluded that adding NSBBs provided no additional benefit to effects
obliteration with cyanoacrylate for the prevention of rebleeding Contraindications and dosage
and mortality.63 Nevertheless, the study was powered to assess Absolute or relative contraindications for NSBBs are present in
a 25% absolute decrease in risk of rebleeding, so a smaller around 15% of patients because of coexisting conditions and, in
reduction in absolute risk of bleeding could not be ruled out. another 15%, dose reduction or withdrawal may be necessary
One small trial compared TIPS to cyanoacrylate injection in 72 because of adverse effects73 (Box 1). These limitations should
patients; TIPS proved more successful in preventing rebleeding not discourage patients and clinicians from using NSBBs for the
from gastric varices, without significant differences regarding indications previously described, given the firm evidence of
survival and adverse events.64 However, TIPS might not be their efficacy in cirrhosis and PH (Table 1).
possible in some of the patients with extrahepatic portal vein Although limited data shows that there is no correlation
occlusion. In these cases, other forms of percutaneous radio- between the decrease in HVPG and a decrease in heart rate,74
logical intervention procedures, such as balloon-occluded current clinical practice recommends an approximate 25%
retrograde transvenous obliteration of gastric varices, and var- decrease in heart rate as evidence of adequate beta-adrenergic
iants of the technique, may be lifesaving. However, a detailed blockade with NSBBs. It is usually advised that NSBBs be
discussion of these procedures is beyond the scope of the cur- titrated until the maximum tolerated dose, provided the sys-
rent review. tolic blood pressure remains above 90 mmHg and heart rate
Bleeding from ectopic varices is very rare in cirrhosis, but is above 55 bpm. Specific data on titration, frequency of
more frequent in patients with extrahepatic portal vein occlu- administration, and maximum doses for each NSBB are pro-
sion, overall representing between 1 and 5% of all gastrointes- vided in Table 2. Once started, NSBBs should be maintained for
tinal haemorrhage in patients with PH.65–67 Ectopic varices are life. According to Baveno I-VI, no endoscopic surveillance is
dilated portovenous vessels located outside of the oesophagus required once patients have achieved a stable maintenance
or the stomach. Anatomic mapping is essential and the het- dose.
erogeneity in localisation limits the implementation of standard
treatment. Current treatment options include endoscopic ther- Side effects
apy, mostly with cyanoacrylate injection or endosonographic NSBBs can have a negative impact on a patient’s quality of life.
coil placement, TIPS with or without embolisation, and balloon- This is mainly due to adverse effects such as worsening fatigue,
occluded retrograde transvenous obliteration.24 There is no data reduced exercise capacity and sexual dysfunction. These
from controlled trials assessing the role of NSBBs in patients symptoms are unspecific and can be attributed to cirrhosis or
with ectopic varices. depression. Therefore, dose reduction or switch to another NSBB
(for instance, carvedilol if the patient was on propranolol or
Portal hypertensive gastropathy nadolol) is recommended rather than discontinuing therapy.
Data is lacking regarding beta-blockers for primary prophylaxis After initiating NSBBs, they should be revaluated periodically as
of bleeding from PHG.68 Two previous studies demonstrated a intolerance or contraindications can develop later on. It is
reduced risk of PHG in patients under NSBBs compared to those currently unknown which threshold of blood pressure and/or
treated only with EBL for bleeding prophylaxis.69,70 One study heart rate and cardiac output reduction can be considered safe,
compared carvedilol vs. propranolol vs. EBL for primary pre- particularly in patients with decompensated cirrhosis. Specific
vention of variceal bleeding, and studied the effect of each studies examining this issue are warranted, although it is clear
treatment on PHG after 1 year. The carvedilol and propranolol that adverse events are dose related. Table 2 indicates the dose
Absolute contraindication
Second-or third-degree AV block (in the absence of a permanent pacemaker)
Critical limb ischemia
Asthma
Cardiogenic shock
Cocaine-induced coronary vasospasm
Known hypersensitivity
Relative contraindication
Uncontrolled diabetes mellitus and hypoglycemia
Raynaud syndrome
Consider reducing the dose or discontinuing the NSBB
Hypotension (systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg)
Development of acute kidney injury/ hepatorenal syndrome
Hyponatremia (serum sodium <130 mEq/L)
Commonly reported adverse effects
Weakness
Shortness of breath
Dizziness
Hypotension
Gastrointestinal symptoms (nausea, constipation)
Sexual and erectile dysfunction
limits for each beta-blocker. Furthermore, since propranolol is carvedilol in order to correct both the arterial and the PH. A
exclusively metabolised by the liver, the dose should be reas- recent study retrospectively assessed the interaction between
sessed for tolerance when liver failure progresses in a given NSBBs and cardiac function on outcomes in patients on a
patient. transplant waiting list (n = 584), which included 32.5% of pa-
tients with refractory ascites. The study showed that refractory
ascites and NSBB use in patients with compromised cardiac
Potential limitations reserve (lower left ventricular stroke work index <64.1 g.m/m2)
Ascites and refractory ascites were associated with increased waiting list mortality in the
In an observational study, Sersté et al. questioned the use of overall group of patients. Nevertheless, the effect of NSBBs on
NSBBs in 151 patients with advanced cirrhosis and suggested mortality in the subset of patients with refractory ascites was
that NSBBs decreased survival in patients with refractory asci- not addressed.82
tes.11 However, a more severe underlying liver disease, higher Table 3 summarises studies on NSBB use in patients with
bilirubin, lower serum sodium, higher prevalence of Child-Pugh ascites and refractory ascites. Attention will be focussed on the
class C, and higher prevalence of high-risk varices in the group most recent and largest studies. Bossen et al. did not find
with NSBBs might justify these differences. Subsequent studies differences in survival between patients taking or not taking
provided evidence on the safety of NSBBs for patients with NSBBs in a post hoc analysis of 1,198 patients with cirrhosis and
refractory ascites.39,40,44,75–80 The deleterious effect of NSBBs ascites (588 with refractory ascites).76 Patients with systolic
reported by Sersté et al.11,81 could also have been related to high blood pressure <80 mmHg or creatinine >150 lmol/L were not
doses of propranolol: nearly half of the patients were receiving included in the study, which may have increased the perception
160 mg/d (and 7 out of 10 patients in the consecutive crossover of safety of NSBBs. Bhutta et al. retrospectively analysed pro-
study). A nationwide study based on Danish registers evaluated spective data from 717 hospitalised patients with cirrhosis and
3,719 patients with cirrhosis and ascites. Propranolol doses ascites, including 366 (51%) patients with refractory ascites,
>160 mg/d were associated with higher mortality than doses revealing no association between NSBBs and a worse
<160 mg/d.40 Since propranolol is metabolised exclusively by outcome.77
the liver, its dose should be restricted in advanced cirrhosis. Aligned with the aforementioned studies, a retrospective
These patients should probably not receive propranolol doses study of 2,419 patients studied the impact of NSBBs on in-
>80 mg/d.78 As for carvedilol, high doses (over 25 mg/day) were hospital mortality. Patients were classified according to the
associated with worse outcomes in patients with refractory presence of varices, ascites or both. In a multivariable model,
ascites.42–44,77,80 As already stated, the recommended dose of NSBBs were significantly associated with increased survival, and
carvedilol for PH is 6.25–12.5 mg/day, as increasing the dose indicated a survival benefit in all groups of patients, including
does not enhance the fall in portal pressure but may cause those with severe ascites. These results were confirmed in a
systemic hypotension. Only the presence of concomitant arterial propensity score matching of a subgroup of 865 patients.39
hypertension in well-compensated cirrhosis – something Onali et al.79 analysed a retrospective cohort of 316 patients
increasingly observed due to the increased prevalence of non- with cirrhosis and ascites considered for liver transplantation
alcoholic fatty liver disease – justify the use of higher doses of (40% with refractory ascites). Patients were classified according
Malandris et al. 201993 Carvedilol vs. other NSBB Studies: 7 trials Bleeding: Carvedilol vs. EBL: RR 0.74
or EBL 4 EBL, 3 NSBB (95% CI 0.37–1.49)
(see rebleeding Patients: 984 Carvedilol vs. propranolol: RR 0.76
section below) Disease stage: most Child-Pugh A and B; (95% CI 0.27–2.14)
Child-Pugh C: 10–49%
Prevention of rebleeding
Bernard et al. 199753 NSBB vs. SCL Studies: 12 trials Rebleeding: NSBB: OR 2.3 (95% CI 1.7–3.0,
Patients: 769 p <0.001)
389 NSBB vs. 380 SCL Overall mortality: survival NSBB: OR 1.4
Disease stage: most Child-Pugh A and B, (95% CI 1.0–1.9, p = 0.04)
Child-Pugh C: 0–35% Bleeding-related mortality: survival NSBB:
OR 1.65 (95% CI 1.1–2.4, p = 0.01)
Adverse events: free of adverse events
higher in NSS vs. SCL: mean difference: 22%
(95% CI 6–38%, p = 0.007)
D’Amico et al. 199927 NSBB vs. placebo/no Studies: 25 trials Rebleeding:
treatment Patients: 1,698 NSBB vs. placebo: ARD = –21% (95% CI –30%
NSBB vs. SCL Disease stage: most Child-Pugh B, to –13%, NNT= 5)
NSBB vs. NSBB + SCL Child-Pugh C: 0–47% NSBB vs. SCL: ARD = 7% (95% CI –2% to 17%)
NSBB vs. NSBB+SCL: ARD = 19%; (95% CI
8%–30%)
Overall mortality: NSBB: ARD = –7% (95%
CI –12% to –2%; NNT = 14)
NSBB vs. NSBB + SCL: ARD 15% (95% CI – 1% to 32%)
Adverse events: NSBB: ARD –22% (95% CI –38%
to –6; NNH = 4)
Cheung et al. 200994 EBL vs. NSSB±ISMN vs. Studies: 12 trials Rebleeding: EBL vs. NSSB±ISMN: RR 1.00
EBL+ NSSB±ISMN 6 EBL vs. NSSB±ISMN (95% CI 0.73–1.37)
4 EBL vs. EBL+ NSSB±ISMN EBL vs. NSSB±ISMN when NSBB
2 EBL+NSSB±ISMN vs. NSSB±ISMN dose <80 mg/d: RR 0.67 (95% CI 0.49–0.91)
Patients: 1,381 EBL+ NSSB±ISMN vs. EBL; RR 0.57 (95% CI
EBL vs. NSBB: 698 0.31–1.08)
Combined vs. EBL: 404 EBL+ NSSB±ISMN vs. NSSB±ISMN: RR 0.76
Combined vs. NSSB±ISMN: 279 (95% CI 0.56–1.03)
Disease stage: Child-Pugh B/C 70–80% Mortality: not significantly different
Adverse events: events between EBL vs.
NSSB±ISMN, but was higher with EBL+
NSSB±ISMN vs. EBL.
Funakoshi et al. 201095 EBL+ NSSB vs. EBL Studies:19 trials Rebleeding: lower EBL group: OR 2.06
SCL+NSBB vs. SCL 4 SCL and 3 EBL (95% CI 1.55–2.73, p <0.0001)
Patients: 1,483 NSBB + SCL/EBL vs. only EBL/SCL reduced
Disease stage: most Child-Pugh B; rebleeding: OR 2.20 (95% CI 1.69–2.85)
Child-Pugh C: 5–35% Overall and Bleeding-related mortality:
No significant difference
Combination therapy lower overall mortality:
OR 1.43 (95% CI 1.03–1.98)
Adverse events (serious): NSBB: OR 2.61
(95% CI 1.60–4.40, p <0.0001)
Thiele et al. 20129 EBL + NSBB±ISMN vs. Studies: 9 trials Rebleeding: Combination therapy: RR 0.68
monotherapy Patients: 955 (95% CI 0.54–0.85, NNT: 8)
(EBL or medical 442 combination vs. 513 monotherapy Overall mortality: Combination: RR 0.89
therapy alone) Disease stage: most Child-Pugh B; (95% CI 0.65–1.21)
Child-Pugh C: 8–22% Bleeding-related mortality: RR 0.52 (95%
CI 0.27–0.99; NNT: 33).
Adverse events: Combination: RR 1.38
(95% CI 1.13–1.68)
Adverse events (serious): RR2.02 (95%
CI 1.14–3.56)
Puente et al. 201455 EBL + NSBB± ISMN Studies: 9 trials Rebleeding: Combination vs. EBL mono:
vs. either 5 EBL vs. EBL + NSBB± ISMN; RR 0.44 (95% CI 0.28–0.69)
treatment alone 4 NSBB± ISMN vs. EBL + NSBB± ISMN Combination vs. NSBB mono: RR 0.76 (95%
Patients: 885 CI 0.58–1.00)
476 + 409 Overall mortality: Combination vs. EBL
Disease stage: most Child-Pugh B; mono: RR 0.58 (95% CI 0.33–1.03)
Child-Pugh C: 13–31% Combination vs. NSBB mono: RR 1.24 (95%
CI 0.90–1.70)
Adverse events: Combination: rebleeding
from oesophageal ulcers increased (p = 0.01)
(continued on next page)
Table 1 (continued)
Albillos et al. 201756 EBL+ NSBB vs. EBL or Studies: individual patient meta-analysis: Rebleeding: EBL + NSBB vs. NSBB: IRR 1.00
NSBB, 7 trials (95% CI 0.68–1.47; p = 0.996), Child-Pugh A:
stratified by 3 EBL + NSBB vs. NSBB IRR 0.40 (95% CI 0.18–0.89, p = 0.025);
cirrhosis severity (Child- 4 EBL + NSBB vs. EBL Child-Pugh B/C: IRR 1.36; (95% CI 0.87–2.14,
Pugh A vs. B/C) Patients: 805 p = 0.180)
389 (vs. NSBB) + 416 (vs. EBL) EBL + NSBB vs. EBL: IRR 0.36 (95% CI
Disease stage: Child-Pugh B/C: 54–89% 0.21–0.59, p <0.001)
Overall mortality: EBL + NSBB vs. NSBB:
IRR 1.19 (95% CI 0.76–1.87; p = 0.449)
EBL + NSBB vs. EBL: IRR 0.50 (95% CI
0.28–0.89, p = 0.019)
Zacharias et al. 201891 Information presented
above in prevention
of first bleeding
Dwinata et al. 201992 Carvedilol vs. EBL Studies: 3 trials Bleeding: Carvedilol: RR 1.10 (95% CI 0.75–1.61)
Patients: 230 Overall mortality: RR 0.51 (95% CI 0.33–0.79)
112 vs. 118
Disease stage: Child-Pugh B 9 (median)
Malandris et al. 201993 Carvedilol vs. propranolol Studies: 7 trials Rebleeding: Carvedilol vs. EBL: RR 1.10
OR NSBB+ISMN OR EBL 3 EBL, 2 NSBBs + ISMN, 2 NSBB (95% CI 0.75–1.61)
Patients: 614 vs. NSBBs+ISMN: RR 1.02 (95% CI 0.70–1.51) vs.
Disease stage most Child-Pugh B7–9 propranolol: RR 0.39 (95% CI 0.15–1.03)
Overall mortality: compared to EBL (3 RCTs),
RR 0.51 (95% CI 0.33–0.79)
Adverse events: No significant differences for
safety compared with EBL and NSBBs
ARD, absolute risk difference; EBL, endoscopic band ligation; IRR, incidence rate ratio; ISMN, isosorbide mononitrate; NNH, number needed to harm; NNT, number needed to
treat; NSBB, non-selective beta-blocker; OR, odds ratio; RR, risk ratio; SCL, sclerotherapy.
to whether they were receiving NSBBs or not at the time of dose 6.25 mg/d) had a mortality risk between those on pro-
transplant. NSBBs were associated with reduced mortality pranolol and those not receiving NSBBs. Sinha R et al.44 analysed
(HR 0.511; CI 0.3–0.87; p = 0.014). 264 patients with cirrhosis and ascites, 132 treated with car-
Regarding studies including carvedilol, Leithead et al. eval- vedilol (median dose 12.5 mg), showing that long-term use of
uated 322 patients with ascites listed for liver transplantation carvedilol was associated with a 41% mortality reduction in
and found a significantly lower waitlist mortality in NSBB patients with mild ascites. In the subset of patients with mod-
users.42 The subgroup of patients receiving carvedilol (median erate or severe ascites, carvedilol did not reduce mortality, but
Table 2. Appropriate dosing, targets and follow-up of available NSBBs for prevention of first bleeding episode in patients with high-risk varices and liver
cirrhosis.
Table 3 (continued)
did not worsen prognosis. In the most recent study, 624 patients decompensated liver cirrhosis are still warranted to ascertain
with ascites were analysed retrospectively.80 Patients receiving whether adverse effects are related to dosage or mainly depend
NSBBs had a significantly higher 28-day transplant-free survival on haemodynamic factors.
than patients not receiving NSBBs (p = 0.014). Results did not
differ between patients on propranolol (median 30 mg/d) and Spontaneous bacterial peritonitis
those on carvedilol (median 12.5 mg/d). These results support In a retrospective study including 607 patients at their first par-
that carvedilol at low doses (6.25–12.5 mg/d) is safe in patients acentesis, Mandorfer et al.38 analysed 182 patients at the first
with decompensated cirrhosis. In a more detailed analysis, the diagnosis of SBP, suggesting that NSBB use was associated with
beneficial effect of NSBBs on survival was attenuated in patients poor outcomes in the subgroup of patients with SBP. These pa-
with a low MAP (<82 mmHg) and was absent in patients with tients had more episodes of HRS and AKI, and decreased
ascites and a MAP <65 mmHg; moreover, the latter group had transplant-free survival. However, in this study, the subset of
increased rates of renal impairment. Thus, despite the benefits patients with SBP taking NSBBs also had higher total bilirubin
of NSBBs, patients with hypotension should be closely moni- levels and lower arterial blood pressure, as well as including a
tored and NSBB dose reduced or withdrawn if hypotension is higher proportion of patients with Child-Pugh C cirrhosis. It is
severe. entirely speculative to ascribe NSBB use to the increased mortality
Three recent meta-analyses of the mostly observational rate, since this could well reflect end-stage liver disease, severe
studies previously mentioned further concluded that NSBB use infection or a combination of different non-identified factors. In
is not associated with increased mortality, including patients contrast, other studies failed to confirm a worse prognosis of
with mild and refractory ascites.83–85 There was significant patients under NSBBs.43,76,77 Bang et al.40 analysed the largest
heterogeneity across these studies. In summary, current evi- series, with 361 patients with SBP and reported that NSBB use was
dence from observational studies does not support withdrawing associated with increased survival. Moreover, among patients
NSBBs in patients with ascites or refractory ascites.76–78 Indeed, with severely decompensated cirrhosis, NSBBs were associated
most studies observed a benefit, with increased survival in with a lower risk of developing SBP. Thus, the data is controversial
patients with refractory ascites treated with NSBBs.39,40,75,79,80 and no firm conclusions can be obtained. However, it is wise to
At Baveno VI, when part of the aforementioned data was still carefully assess patients with SBP if they are receiving NSBBs and
unavailable, it was recommended that the NSBB dose should be reduce their dose or stop their administration in cases of severe
reduced or discontinued in the case of hypotension (systolic hypotension or severe AKI. Of note, NSBBs decrease the incidence
blood pressure <90 mmHg), hyponatremia (serum sodium of SBP, so they should not be prohibited in patients with ascites,
<130 mEq/L) or the development of acute kidney injury (AKI).22 even in those with previous SBP episode(s).8
It was further suggested that discontinuation of NSBBs should
be temporary and that they should be carefully reinstated after Acute-on-chronic liver failure
resolution of the event. Patients with ACLF present an inflammatory status that can
Current EASL guidelines recommend that propranolol should be associated with renal failure and circulatory dysfunction,
not exceed daily doses >80 mg/d based on observational so a concern was raised with regards to NSBB use since these
data(23). Although they do not recommend carvedilol in pa- patients frequently have sepsis or AKI. Nevertheless,43 a sub-
tients with ascites, several recent studies have emerged to analysis of the CANONIC study with 349 hospitalised patients
support its use and safety at low doses (6.25–12.5 mg/d) in with ACLF, showed that NSBB administration improved 28-day
these patients.42–44,77,80 In light of the available evidence, in survival in patients with ACLF. A potential mechanism could
patients with refractory ascites, carvedilol can probably be used be increased gut motility and reduced bacterial translocation
safely at low doses (6.25–12.5 mg/day), provided the patient known to be caused by beta-blockade, which in turn may
maintains a systolic blood pressure over 90 mmHg. Neverthe- decrease systemic inflammation. More recently, Tergast et al.80
less, the limits both for doses and for “safe” circulatory pa- reported better survival in 254 patients with ACLF under
rameters are not currently evidence based, so further NSBBs. NSBB use remained a positive prognostic factor after
prospective studies assessing NSBB use in patients with adjusting for potential confounders in a multivariate model,
while early interruption of NSBBs was associated with lower contraindications. The advent of agents more effective than
28-day transplant-free survival. Consequently, there is no evi- propranolol, such as carvedilol, could potentially render hae-
dence for NSBB withdrawal in ACLF. modynamic monitoring unnecessary even in clinical trials. Non-
Table 3 describes the results, strengths and limitations of invasive markers to monitor beta-blocker response are still
most recent studies for and against NSBB use in refractory as- currently unavailable.
cites, SBP and ACLF in advanced cirrhosis. Most of the evidence For secondary prophylaxis, in patients receiving NSBBs plus
comes from observational studies, as no specific RCT of NSBB EBL (complemented or not with low doses of a lipophilic statin,
use has been carried out in these scenarios. As a result, these such as simvastatin), TIPS is the best rescue treatment. Primary
studies are prone to many potential biases: short follow-up prophylaxis failures treated with either NSBBs or EBL have no
duration (median 28 days to 27 months); heterogeneous pop- current recommended treatment option due to the lack of RCTs
ulation (discrepant definitions for refractory ascites and AKI, in this setting. De Souza et al.88 analysed 89 patients and found
and different NSBB doses); lack of information on titration an increased risk of rebleeding and death in patients with an
strategy, and policy for stopping/resuming NSBBs. index bleed while under NSBBs. These patients (clinical NSBB
Moreover, these studies have an important inherent bias non-responders) might benefit from more aggressive therapy,
when comparing patients receiving NSBBs or not. Patients on such as TIPS, particularly if the patients have high-risk features,
NSBBs tend to have more advanced cirrhosis and higher prev- namely, ascites or portal vein thrombosis, and an absence of
alence of high-risk varices than those not receiving NSBBs. This contraindications.24
bias is difficult to avoid without randomisation, despite the use
of propensity scores or multivariate analysis.86 Nevertheless,
evidence from these studies strongly suggests that NSBBs are Conclusions
not absolutely contraindicated in patients with ascites, re- In summary, the indication to start NSBBs has expanded
fractory ascites, SBP and ACLF,76–78 and 3 independent meta- recently beyond the setting of PH-associated bleeding to pre-
analyses confirmed this data.83,84,87 vention of decompensation in patients with compensated
cirrhosis. Doses must be titrated and re-evaluated in all patients,
Non-response to non-selective beta-blockers particularly those with decompensated cirrhosis and with
Currently with carvedilol as an alternative to propranolol, only deteriorating liver failure. Data from observational studies are
a small proportion of patients remain haemodynamic non- contradictory regarding the safety of NSBBs in patients with
responders. Since measurements of HVPG are not done refractory ascites or infection. Future RCTs should include pa-
routinely in clinical practice, the decision to use NSBBs is based tients with decompensated cirrhosis to assess efficacy, dose
on its known beneficial effects and the absence of tolerance limits, and safety.
Abbreviations References
ACLF, acute-on-chronic liver failure; AKI, acute kidney injury; ALD, [1] Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol–a medical
alcohol-related liver disease; ARD, absolute risk difference; AV, atrio- treatment for portal hypertension? Lancet 1980;2(8187):180–182.
ventricular; EBL, endoscopic band ligation; GOV, gastroesophageal [2] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage
varices; HRS, hepatorenal syndrome; HVPG, hepatic venous pressure in cirrhosis. N Engl J Med 2010;362(9):823–832.
gradient; IGV, isolated gastric varices; IRR, incidence rate ratio; ISMN, [3] Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention
isosorbide mononitrate; MAP, mean arterial pressure; NASH, non-alco- of recurrent gastrointestinal bleeding in patients with cirrhosis: a
holic steatohepatitis; NNH, number needed to harm; NNT, number controlled study. N Engl J Med 1981;305(23):1371–1374.
needed to treat; NR, not reported; NSBBs, non-selective beta-blockers; [4] Pascal JP, Cales P. Propranolol in the prevention of first upper gastroin-
OR, odds ratio; PH, portal hypertension; PHG, portal hypertensive gas- testinal tract hemorrhage in patients with cirrhosis of the liver and
esophageal varices. N Engl J Med 1987;317(14):856–861.
tropathy; RCT, randomised controlled trials; RR, risk ratio; SBP, sponta-
[5] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet
neous bacterial peritonitis; SCL, sclerotherapy; TIPS, transjugular
2014;383(9930):1749–1761.
intrahepatic portosystemic shunt.
[6] Perez-Ayuso RM, Pique JM, Bosch J, Panes J, Gonzalez A, Perez R, et al.
Propranolol in prevention of recurrent bleeding from severe portal hy-
Financial support pertensive gastropathy in cirrhosis. Lancet 1991;337(8755):1431–1434.
The authors received no financial support to produce this manuscript. [7] Lo GH, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA, et al. Improved
survival in patients receiving medical therapy as compared with banding
Conflict of interest ligation for the prevention of esophageal variceal rebleeding. Hepatology
The authors declare no conflicts of interest that pertain to this work. 2008;48(2):580–587.
Please refer to the accompanying ICMJE disclosure forms for further [8] Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D,
details. et al. beta-Blockers protect against spontaneous bacterial peritonitis in
cirrhotic patients: a meta-analysis. Liver Int 2009;29(8):1189–1193.
[9] Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and
Authors’ contributions medical interventions for the prevention of rebleeding from oesophageal
varices. Aliment Pharmacol Ther 2012;35(10):1155–1165.
SGR and YPM performed the systematic review of the literature
[10] Wilkinson RP. Propranolol and portal hypertension in cirrhosis. Lancet
and drafted the manuscript. JB supervised, drafted and revised 1980;2(8191):429.
the manuscript. [11] Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Delete-
rious effects of beta-blockers on survival in patients with cirrhosis and
Supplementary data refractory ascites. Hepatology 2010;52(3):1017–1022.
Supplementary data to this article can be found online at https://doi. [12] Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemo-
org/10.1016/j.jhepr.2019.12.001. dynamic and non-haemodynamic effects of beta-blockers improve
[50] Bhardwaj A, Kedarisetty CK, Vashishtha C, Bhadoria AS, Jindal A, cirrhosis. The New Italian Endoscopic Club for the study and treatment of
Kumar G, et al. Carvedilol delays the progression of small oesophageal esophageal varices (NIEC). Gastroenterology 2000;119(1):181–187.
varices in patients with cirrhosis: a randomised placebo-controlled trial. [73] Longacre AV, Imaeda A, Garcia-Tsao G, Fraenkel L. A pilot project
Gut 2017;66(10):1838–1843. examining the predicted preferences of patients and physicians in the
[51] Qi XS, Bao YX, Bai M, Xu WD, Dai JN, Guo XZ. Nonselective beta-blockers primary prophylaxis of variceal hemorrhage. Hepatology 2008;47(1):
in cirrhotic patients with no or small varices: a meta-analysis. World J 169–176.
Gastroenterol 2015;21(10):3100–3108. [74] Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM,
[52] Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Patrick MJ, et al. Short-term effects of propranolol on portal venous
et al. Hepatic venous pressure gradient predicts clinical decompensation pressure. Hepatology 1986;6(1):101–106.
in patients with compensated cirrhosis. Gastroenterology 2007;133(2): [75] Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, et al.
481–488. Non-selective b-blockers are associated with improved survival in pa-
[53] Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic tients with ascites listed for liver transplantation. Gut 2015;64(7):
antagonists in the prevention of gastrointestinal rebleeding in patients 1111–1119.
with cirrhosis: a meta-analysis. Hepatology 1997;25(1):63–70. [76] Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P. Nonselective b-blockers
[54] Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate do not affect mortality in cirrhosis patients with ascites: post hoc anal-
alone or with either beta-blockers or endoscopic therapy for the man- ysis of three randomized controlled trials with 1198 patients. Hepatology
agement of oesophageal varices. Aliment Pharmacol Ther 2010;32(7): 2016;63(6):1968–1976.
859–871. [77] Bhutta AQ, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, O’Leary JG, et al.
[55] Puente A, Hernandez-Gea V, Graupera I, Roque M, Colomo A, Poca M, Beta-blockers in hospitalised patients with cirrhosis and ascites: mor-
et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated tality and factors determining discontinuation and reinitiation. Aliment
systematic review. Liver Int 2014;34(6):823–833. Pharmacol Ther 2018;47(1):78–85.
[56] Albillos A, Zamora J, Martinez J, Arroyo D, Ahmad I, De-la-Pena J, et al. [78] Robins A, Bowden A, Watson W, Smith F, Gelson W, Griffiths W. Beta-
Stratifying risk in the prevention of recurrent variceal hemorrhage: re- blockers in cirrhosis patients with refractory ascites. Hepatology
sults of an individual patient meta-analysis. Hepatology 2017;66(4): 2014;59(5):2054–2055.
1219–1231. [79] Onali S, Kalafateli M, Majumdar A, Westbrook R, O’Beirne J, Leandro G,
[57] Lo GH, Chen WC, Wang HM, Yu HC. Randomized, controlled trial of et al. Non-selective beta-blockers are not associated with increased
carvedilol versus nadolol plus isosorbide mononitrate for the prevention mortality in cirrhotic patients with ascites. Liver Int 2017;37(9):
of variceal rebleeding. J Gastroenterol Hepatol 2012;27(11):1681–1687. 1334–1344.
[58] Stanley AJ, Dickson S, Hayes PC, Forrest EH, Mills PR, Tripathi D, et al. [80] Tergast TL, Kimmann M, Laser H, Gerbel S, Manns MP, Cornberg M, et al.
Multicentre randomised controlled study comparing carvedilol with Systemic arterial blood pressure determines the therapeutic window of
variceal band ligation in the prevention of variceal rebleeding. J Hepatol non-selective beta blockers in decompensated cirrhosis. Aliment Phar-
2014;61(5):1014–1019. macol Ther 2019;50(6):696–706.
[59] Yang J, Ge K, Chen L, Yang JL. The efficacy comparison of carvedilol plus [81] Serste T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Beta-
endoscopic variceal ligation and traditional, nonselective beta-blockers blockers cause paracentesis-induced circulatory dysfunction in patients
plus endoscopic variceal ligation in cirrhosis patients for the preven- with cirrhosis and refractory ascites: a cross-over study. J Hepatol
tion of variceal rebleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2011;55(4):794–799.
2019;31(12):1518–1526. [82] Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, et al.
[60] Korula J, Chin K, Ko Y, Yamada S. Demonstration of two distinct subsets Impact of cardiac function, refractory ascites and beta blockers on the
of gastric varices. Observations during a seven-year study of endoscopic outcome of patients with cirrhosis listed for liver transplantation.
sclerotherapy. Dig Dis Sci 1991;36(3):303–309. J Hepatol 2019 [Epub ahead of print].
[61] Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, [83] Chirapongsathorn S, Valentin N, Alahdab F, Krittanawong C, Erwin PJ,
classification and natural history of gastric varices: a long-term follow- Murad MH, et al. Nonselective b-blockers and survival in patients with
up study in 568 portal hypertension patients. Hepatology 1992;16(6): cirrhosis and ascites: a systematic review and meta-analysis. Clin Gas-
1343–1349. troenterol Hepatol 2016;14(8):1096–1104.e9.
[62] Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric [84] Facciorusso A, Roy S, Livadas S, Fevrier-Paul A, Wekesa C, Kilic ID, et al.
variceal bleeding comparing cyanoacrylate injection and beta-blockers: Nonselective beta-blockers do not affect survival in cirrhotic patients
a randomized controlled trial. J Hepatol 2011;54(6):1161–1167. with ascites. Dig Dis Sci 2018;63(7):1737–1746.
[63] Hung HH, Chang CJ, Hou MC, Liao WC, Chan CC, Huang HC, et al. Efficacy [85] Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing
of non-selective beta-blockers as adjunct to endoscopic prophylactic the safety of beta-blocker therapy in cirrhosis patients with ascites: a
treatment for gastric variceal bleeding: a randomized controlled trial. meta-analysis. Liver Int 2019;39(6):1080–1088.
J Hepatol 2012;56(5):1025–1032. [86] Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in pa-
[64] Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, et al. A prospective, tients with advanced liver disease: has the dust settled? Liver Transpl
randomized controlled trial of transjugular intrahepatic portosystemic 2017;23(8):1058–1069.
shunt versus cyanoacrylate injection in the prevention of gastric variceal [87] Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with
rebleeding. Endoscopy 2007;39(8):679–685. cirrhosis and ascites: type of beta-blocker matters. Gut 2016;65(8):
[65] Henry Z, Uppal D, Saad W, Caldwell S. Gastric and ectopic varices. Clin 1393–1394.
Liver Dis 2014;18(2):371–388. [88] de Souza AR, La Mura V, Reverter E, Seijo S, Berzigotti A, Ashkenazi E,
[66] Lebrec D, Benhamou JP. Ectopic varices in portal hypertension. Clin et al. Patients whose first episode of bleeding occurs while taking a
Gastroenterol 1985;14(1):105–121. b-blocker have high long-term risks of rebleeding and death. Clin Gas-
[67] Norton ID, Andrews JC, Kamath PS. Management of ectopic varices. troenterol Hepatol 2012;10(6):670–676. quiz e58.
Hepatology 1998;28(4):1154–1158. [89] Tripathi D, Graham C, Hayes PC. Variceal band ligation versus beta-
[68] Cubillas R, Rockey DC. Portal hypertensive gastropathy: a review. Liver blockers for primary prevention of variceal bleeding: a meta-analysis.
Int 2010;30(8):1094–1102. Eur J Gastroenterol Hepatol 2007;19(10):835–845.
[69] Lo GH, Lai KH, Cheng JS, Hsu PI, Chen TA, Wang EM, et al. The effects of [90] Bai M, Qi X, Yang M, Han G, Fan D. Combined therapies versus mono-
endoscopic variceal ligation and propranolol on portal hypertensive gas- therapies for the first variceal bleeding in patients with high-risk vari-
tropathy: a prospective, controlled trial. Gastrointest Endosc 2001;53(6): ces: a meta-analysis of randomized controlled trials. J Gastroenterol
579–584. Hepatol 2014;29(3):442–452.
[70] Sarin SK, Shahi HM, Jain M, Jain AK, Issar SK, Murthy NS. The natural [91] Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY.
history of portal hypertensive gastropathy: influence of variceal eradi- Carvedilol versus traditional, non-selective beta-blockers for adults with
cation. Am J Gastroenterol 2000;95(10):2888–2893. cirrhosis and gastroesophageal varices. Cochrane database Syst Rev
[71] Hosking SW, Kennedy HJ, Seddon I, Triger DR. The role of propranolol in 2018;10:CD011510.
congestive gastropathy of portal hypertension. Hepatology 1987;7(3): [92] Dwinata M, Putera DD, Adda’i MF, Hidayat PN, Hasan I. Carvedilol vs
437–441. endoscopic variceal ligation for primary and secondary prevention of
[72] Primignani M, Carpinelli L, Preatoni P, Battaglia G, Carta A, Prada A, et al. variceal bleeding: systematic review and meta-analysis. World J Hepatol
Natural history of portal hypertensive gastropathy in patients with liver 2019;11(5):464–476.